Sponsored by
Very exciting news. As I mentioned in a few previous posts (such as https://virtualtrials.org/newsarticle.cfm?item=6750) , the G47 Delta virus did remarkably well in a phase 2 trial for recurrent or residual Glioblastoma. They reported a 1 year survival rate of 92% compared to historical controls of 15%. This article says they applied for the Japanese equivalent of our FDA approval for it last month. So at least in Japan, there will hopefully be a new, effective Glioblastoma treatment soon. We have to work on getting it here in the USA.